Technical Analysis for COYA - Coya Therapeutics, Inc.

Grade Last Price % Change Price Change
F 4.61 -3.56% -0.17
COYA closed down 3.56 percent on Thursday, January 26, 2023, on 3.47 times normal volume.

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent N/A N/A Down

Date Alert Name Type % Chg
Volume Surge Other 0.00%
Doji - Bullish? Reversal 0.00%
Gapped Down Weakness 0.00%
Hammer Candlestick Bullish -2.95%
Lizard Bullish Bullish Day Trade Setup -2.95%
Hot IPO Pullback Bullish Swing Setup -2.95%
Hammer Candlestick Bullish -3.35%
Hot IPO Pullback Bullish Swing Setup -3.35%
180 Bullish Setup Bullish Swing Setup -3.35%
Hot IPO Pullback Bullish Swing Setup -3.35%

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.


Coya Therapeutics, Inc. Description

Coya Therapeutics, Inc., a clinical-stage biotechnology company, develops proprietary medicinal products to modulate the function of regulatory T cells (Tregs). The company's product candidate pipeline is based on therapeutic modalities, such as Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy. It is developing COYA 101, an autologous regulatory T-cell product candidate that has completed Phase 2a clinical trial for use in the treatment of Amyotrophic Lateral Sclerosis. The company's product candidates in IND-enabling studies include COYA 301, a Treg-enhancing biologic for use in the treatment of Frontotemporal Dementia; and COYA 302, a biologic combination for subcutaneous and/or intravenous administration intended to enhance Treg function while depleting T effector function and activated macrophages for use in the treatment of neurodegenerative and autoimmune diseases. It is also developing COYA 201, an allogeneic Treg exosome product candidate that is in preclinical stage for use in the treatment of neurodegenerative, autoimmune, and metabolic diseases; and COYA 206, an antigen directed Treg-derived exosome product candidate, which is in discovery stage. The company was incorporated in 2020 and is headquartered in Houston, Texas.


Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biotechnology Immunology Immune System Cell Therapy Metabolic Disease Amyotrophic Lateral Sclerosis Exosome T Cells Frontotemporal Dementia Medicinal Products

Is COYA a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength


Indicator Value
52 Week High 5.21
52 Week Low 4.5
Average Volume 15,409
200-Day Moving Average 0.00
50-Day Moving Average 0.00
20-Day Moving Average 0.00
10-Day Moving Average 4.74
Average True Range 0.22
RSI 49.24
ADX 0.0
+DI 13.95
-DI 11.30
Chandelier Exit (Long, 3 ATRs) 4.56
Chandelier Exit (Short, 3 ATRs) 5.15
Upper Bollinger Bands 0.00
Lower Bollinger Band 0.00
Percent B (%b) 0.0
BandWidth 0.00
MACD Line -0.01
MACD Signal Line 0.00
MACD Histogram -0.0061
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 4.87
Resistance 3 (R3) 4.86 4.76 4.82
Resistance 2 (R2) 4.76 4.70 4.77 4.81
Resistance 1 (R1) 4.69 4.66 4.73 4.70 4.79
Pivot Point 4.59 4.59 4.61 4.60 4.59
Support 1 (S1) 4.52 4.53 4.56 4.53 4.43
Support 2 (S2) 4.42 4.49 4.43 4.41
Support 3 (S3) 4.35 4.42 4.40
Support 4 (S4) 4.36